Dr Kinan Mokbel

Academic Lecturer in Clinical Pharmacy and Pharmacology, and Clinical Research Fellow

Dr. Kinan Mokbel is a pharmacist with over 19 years of expertise spanning healthcare practice and clinical research. As a committed academic and educator, he has delivered high-level teaching across undergraduate, postgraduate and professional development programmes for registered pharmacists. He holds academic leadership as module lead on the following key courses within both the MSc Clinical Pharmacy and MSc Advanced Clinical Practice programmes:

• HPDM156: Long-Term Condition Care (Respiratory, Endocrine, and Renal)
• HPDM157: Long-Term Condition Care (Cardiovascular)

Kinan is also the Lead for Pharmacology curriculum at the Nursing Academy, where he delivers pharmacology teaching across all four years of the MSci Nursing programme, supporting nursing students at every stage of their training. The programme offers pathways in Adult Nursing or a combined Adult and Mental Health Nursing specialism. This four-year integrated Master’s degree leads to an MSci Nursing qualification and registration with the Nursing and Midwifery Council (NMC) as an Adult Nurse, with the possibility for some students to achieve a dual registration in Adult and Mental Health Nursing. The curriculum is designed to provide a comprehensive education, blending theoretical knowledge with hands-on clinical experience, to prepare students for the complexities of modern nursing practice.

In addition to his teaching, Kinan is a Clinical Research Fellow for the ERASE-LC study, acting as the primary contact for patients. He is responsible for coordinating the safe delivery of clinical assessments and treatments, ensuring participants receive high standards of care throughout the clinical trial. Previously, Kinan held a Postdoctoral Research Fellowship in the Department of Health and Community Sciences at the University of Exeter, where he was involved in the Spotting Cancer among Comorbidities (SPOCC) programme - an NIHR-funded initiative led by the APEx team in collaboration with University College London. His research focused on understanding patient help-seeking behaviours and how primary care professionals identify early signs of cancer, particularly in patients with existing comorbidities. The programme aims to reduce diagnostic delays and improve cancer survival rates through more effective symptom recognition and referral strategies.

Kinan also holds an honorary senior research fellowship at the London Breast Institute at the Princess Grace Hospital, London, since 2016. In this role, he collaborates with a multidisciplinary team on research related to the influence of genetics on treatment response and the development of new breast cancer drugs.

"I am open to supervising or co-supervising highly motivated undergraduate, MSc, and PhD students in areas aligned with my research expertise and interests. I also welcome inquiries from visiting students or scholars interested in collaboration. Feel free to reach out via email".

Qualifications

• Master of Pharmacy
• Post-graduate Certificate in Pharmacy Education Development
• Master of Science in Clinical Pharmacy
• Master of Science in Genomic Medicine
• PhD - Pharmacogenomics of Medically Important Adverse Drug Effects
• Learning & Teaching in Higher Education (LTHE)
• ASPIRE Higher Education Academy Associate Fellowship
• Fellow of the Higher Education Academy (FHEA)

Research projects

• ERASE – long COVID (Clinical feasibility study of the efficacy of Remdesivir for long COVID)
• SPOCC: SPOtting Cancer among Comorbidities.
• Pharmacogenomics of Medically Important Adverse Drug Effects. Learn about genomic medicine and pharmacy practice.
• Assessing the prevalence of genotypes conferring risk of severe adverse drug reactions in participants of UK Biobank. Learn about Genomics for Pharmacy and its significance in pharmacy practice.

Research group links

• Exeter Collaboration for Academic Primary Care (APEx)
• ERASE – long COVID (Clinical feasibility study of the efficacy of Remdesivir for long COVID)

Research interests

• Spotting cancer among comorbidities and supporting clinical decision-making in patients with symptoms of cancer and pre-existing conditions.
• Safety of medicines in general practice.
• The role of community pharmacists in addressing adverse drug effects.
• Genomic profiling scores for chemotherapy recommendations in women with breast cancer.
• Prognostication tools in the context of adjuvant treatment of early breast cancer.
• Long COVID
• Genetic testing in clinical practice.
• Chemoprevention of breast and prostate cancers with vitamins and micronutrients.

Conferences and invited presentations

The Clinical Pharmacy Congress 9-10 May 2025, London, England. Expanding Pharmacy Services with Point-of-Care Testing for Strep A as a Model for Future Care - Driving Down Antibiotic Prescriptions from the Heart of the Community through Point-of-Care Testing. Author URL.

Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) September 23-25, 2024 at the Ohio State University in Columbus, Ohio, USA. Atlas of Pharmacogenomic Variants Underpinning Adverse Drug Effects: Unveiling Critical Insights for Advancing Precision Medicine. Author URL.

The Clinical Pharmacy Congress 10-11 May 2024, London, England. The Impact of the COVID-19 Pandemic on Medication Prescribing Patterns in General Practice: A Retrospective Time-trend Analysis. Abstract.

The Clinical Pharmacy Congress North 3-4 November 2023, Manchester, England. A Nationwide Comparative Safety Study of Medicines Within the Therapeutic Class: A Novel Data Integration Approach Based on the Yellow Card Reporting Scheme and the English General Practice Prescription Data. Abstract.

The 7th International Congress of the European Society for Pharmacogenomics and Personalised Therapy (ESPT), October 25-27th, 2023, Copenhagen, Denmark. Pharmacogenomic Variants of Medically Important Adverse Effects Related to High-Risk Medicines in General Practice Can Not Be Replicated in UK Biobank. Abstract.

The 16th Annual Meeting of Korean Society of Medical Oncology & 2023 International Conference & 11th International FACO Conference, September 7th to 8th 2023, Seoul, Korea. Pharmacogenetics of Endocrine Therapy Associated Toxicities in Breast Cancer. Author URL.

The European Society of Human Genetics Conference, June 10–13th, 2023, Glasgow, Scotland, UK. The Majority of Pharmacogenomic Variants Associated with Adverse Drug Events When Taking Endocrine Therapies for Breast Cancer Can Not Be Replicated in UK Biobank Participants. Author URL.

The Association for Cancer Surgery Annual Scientific Conference and NCRI Cancer Conference 5th–8th November 2017 Liverpool, UK. A comparison of the performance of EndoPredict Clinical and NHS PREDICT in 120 patients treated for ER+ breast cancer. Author URL.

Accepted Manuscript(s)

• Evaluating Genotype-Treatment Interactions for High-Risk Medications in British General Practice: Evidence from UK Biobank

Manuscript(s) under consideration

• Endocrine Therapy and Medically Important Adverse Drug Effects: A Pharmacogenomic Investigation in Breast Cancer Patients in UK Biobank.
• Preoperative Diagnostic Gaps and Evolving Standards in Early Breast Cancer Management: Insights from the CONSCIENCE Study